Medication info
Lostel Tablet 40/5 mg

Lostel Tablet 40/5 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Samchundang Pharmaceutical Co., Ltd.
Appearance
Light pink oval film-coated tablet
Packaging
30 tablets (10 tablets/Alu-Alu) x 3
Approval status
Active

MFDS item code 201506819 · Approved 2015.09.25 · Insurance code 651204410

Summary

Main use
Treatment of dyslipidemia and hypertension, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine produces an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after initiation of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.

Ingredients

Manufacturer
Samchundang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia and hypertension, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication contains two active ingredients: Telmisartan and Rosuvastatin. Telmisartan is primarily used to treat essential hypertension and helps reduce the risk of cardiovascular diseases such as myocardial infarction or stroke in older high-risk patients. Rosuvastatin works by controlling hypercholesterolemia and dyslipidemia, lowering blood cholesterol levels, and delaying the progression of atherosclerosis. Additionally, it contributes to reducing the risk of stroke, myocardial infarction, and arterial revascularization in patients at high risk for cardiovascular diseases. Therefore, this medication is used to improve cardiovascular health in patients with both hypertension and hyperlipidemia.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine produces an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after initiation of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.

Precautions

This medication can cause severe harm to the fetus and newborn if taken during pregnancy, so it should be stopped immediately upon confirmation of pregnancy. Women who are hypersensitive to this medication, pregnant or nursing, and fertile women who are not using appropriate contraception should not take this medication. Patients with severely impaired liver function, those with bile excretion issues, and patients with certain kidney diseases or myopathy should also avoid using this medication. Elderly patients, those with hyperkalemia, and patients with mild liver dysfunction should use this medication cautiously, and patients at risk of muscle-related side effects should exercise extra caution. This medication may affect the liver and muscles, so liver function tests and muscle enzyme tests should be performed regularly before and during treatment. If symptoms such as myalgia, weakness, or cramps occur, consult healthcare professionals immediately, and discontinue use if severe. This medication may interact with other drugs, so inform healthcare providers of any other medications being taken. Caution is particularly needed when used in conjunction with antihypertensives, diuretics, potassium supplements, certain antibiotics, antifungals, and immunosuppressants. It is advisable to avoid or minimize alcohol consumption during treatment, especially with a history of liver disease. Use caution when driving or operating dangerous machinery due to the potential for dizziness or drowsiness. Keep this medication out of reach of children and do not transfer it to other containers for safety. In case of overdose, visit a medical institution immediately for appropriate treatment, as symptoms such as hypotension or kidney function abnormalities may occur.

Side effects

Headache, positional dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, discomfort in the oropharynx, lung disease, unspecified gastrointestinal disorders, benign gastrointestinal neoplasms, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory tract infections, urinary tract infections, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, indigestion, abdominal bloating, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver disorders, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, angioedema, diabetes, headache, dizziness, constipation, nausea, pancreatitis, pruritus, rash, urticaria, myalgia, muscle myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and systemic symptoms accompanying drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, oculobulbar weakness, facial spasms, sensory disturbances, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, facial edema, alopecia, conjunctivitis, tinnitus, petechial hemorrhage, palpitations, fatigue, nausea, lack of effectiveness, weakness, edema, decreased libido, facial edema, rash, alopecia, conjunctivitis, tinnitus, petechial hemorrhage, headache, dizziness, cough, indigestion, chest pain, myalgia, increased CK, constipation, increased AST, weakness, arthralgia, fatigue, numbness, sensory disturbances, chest discomfort, nausea, abdominal pain, diarrhea, anorexia, abdominal bloating, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine, hypotension, tachycardia, bradycardia, dizziness, acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. Maintaining a storage temperature between 1 and 30 degrees Celsius at room temperature is advisable. This helps to safely preserve the medication's efficacy over a longer period.

Appearance and packaging

Appearance

Light pink oval film-coated tablet

Package unit

30 tablets (10 tablets/Alu-Alu) x 3

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.